Bli medlem
Bli medlem

Du är här



AstraZeneca provided an update on the rapid development of its
oncology pipeline at a briefing for analysts and investors on 2 May
2014, as compelling data from over 40 scientific abstracts related to
AstraZeneca and MedImmune investigational medicines were presented at
the American Society of Clinical Oncology (ASCO) meeting in Chicago.

Pascal Soriot, Chief Executive Officer of AstraZeneca said: "ASCO 2014
is a pivotal meeting for AstraZeneca - we have a lot to be proud of.
Our growing oncology pipeline is underpinned by exciting science and
great talent. We have compelling new data on important mid to late
stage assets, which clearly demonstrate our potential to transform
the way cancer is treated and the right people to move them forward.
We remain resolute in our ambition to bring these next-generation
cancer medicines to patients as fast as possible."

Highlights of the analyst and investor presentation were:

Small molecules

Data from the large Phase I study of AZD9291 (presented on Saturday 31
May) showed strong activity as a once-daily monotherapy, with
clinical responses observed in an EGFRm+ population of patients with
non-small cell lung cancer (NSCLC) who previously failed on EGFR TKIs
and also in patients with the T790M resistance mutation. 94% of T790M
positive (T790M+) patients saw their tumours shrink or become stable.
In addition, 64% of T790M+ patients achieved tumour shrinkage of 30%
or more. The most common adverse events were low grade diarrhoea rash
and nausea.

The company anticipates filing for regulatory approval in the United
States for AZD9291 in the second half of 2015 or potentially as early
as the first quarter.

Data from a Phase II study by the US National Cancer Institute (NCI)
were presented as a late-breaking abstract (Saturday 31 May),
investigating the combination of olaparib and cediranib in patients
with platinum-sensitive high-grade serous ovarian cancer. The data
showed that the combination of the two orally-administered
investigational medicines nearly doubled the time it took for
patients' tumours to progress (progression-free survival) and
improved objective response rate (ORR), compared to treatment with
olaparib alone.

AstraZeneca supports the NCI's plans to move the combination forward
into Phase III development.

Briggs Morrison, Executive Vice President and Chief Medical Officer
said: "This is extremely exciting data and among the longest
progression-free survival seen by treatments for patients with
platinum-sensitive high-grade serous ovarian cancer. What is even
more compelling is that the combination of olaparib and cediranib has
the potential to replace chemotherapy. We look forward to seeing the
combination move into Phase III to further explore the potential
benefits for patients who currently have very limited treatment


Multiple Phase I data sets for MEDI4736 - MedImmune's investigational,
engineered, human monoclonal antibody directed against programmed
cell death ligand 1 (PD-L1) -showed durable clinical activity and
tolerability across a range of tumour types.

In the Phase I dose escalation study, reduction of tumour burden was
seen at multiple dose levels as early as six weeks, and clinical
activity was maintained over one year. There was a very low frequency
of drug-related serious adverse events, and no dose-limiting
toxicities were observed.

Data from the dose expansion phase provided further information on the
clinical activity and tolerability profile of MEDI4736, showing early
evidence of clinical activity in over 300 patients in multiple tumour

The Phase I study results, coupled with the pre-clinical data and
validation of this target, supported the recent acceleration of
MEDI4736 into Phase III clinical trials.

At the analyst and investor briefing AstraZeneca also confirmed the
enlarged recruitment target for the tremelimumab Phase II study in
mesothelioma, making it a registration trial.

In addition to data presented at ASCO, AstraZeneca also provided an
update on the Phase I dose escalation study of MEDI4736 in
combination with tremelimumab for patients with refractory NSCLC.
Early data has shown encouraging efficacy for the combination in
NSCLC and no dose limiting toxicities across the five dose levels
assessed to date.

AstraZeneca plans to initiate a Phase III study investigating MEDI4736
in combination with tremelimumab for patients with NSCLC, as an
additional arm of the ARCTIC clinical programme.

Bahija Jallal, Executive Vice President, MedImmune said:
"Immuno-oncology is transforming the landscape of cancer treatment.
It is developing at a rapid pace and we're excited to play a key role
in this critical area with our promising science. With the
AstraZeneca and MedImmune combined portfolios, we are uniquely
positioned to explore this promising therapeutic approach and have
already initiated multiple combination studies with MEDI4736."

Audio replay and the presentation from the analyst and investor event
will be available on the investor pages of the AstraZeneca website
here (

- ENDS -


About AstraZeneca

AstraZeneca is a global, innovation-driven biopharmaceutical business
that focuses on the discovery, development and commercialisation of
prescription medicines, primarily for the treatment of
cardiovascular, metabolic, respiratory, inflammation, autoimmune,
oncology, infection and neuroscience diseases. AstraZeneca operates
in over 100 countries and its innovative medicines are used by
millions of patients worldwide. For more information please visit:


Media Enquiries

Esra Erkal-Paler +44 20 7604 8030 (UK/Global)

Ayesha Bharmal +44 20 7604 8034 (UK/Global)

Michele Meixell + 1 302 885 6351 (US)

Jacob Lund +46 8 553 260 20 (Sweden)

Investor Enquiries

Karl Hård +44 20 7604 8123  mob: +44 7789 654364

Colleen Proctor + 1 302 886 1842 mob: +1 302 357 4882

Anthony Brown +44 20 7604 8067 mob: +44 7585 404943

Jens Lindberg +44 20 7604 8414 mob: +44 7557 319729


Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.